Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 2/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10070993 | 0.83 | CYP1A2 (0.43) | BCHEACHE | |
| SCHEMBL10070138 | 0.81 | BCHE (0.36) | BCHEACHE | |
| SCHEMBL10041195 | 0.81 | CDK5 (0.38) | CDK5CDK5R1GSK3BCDK1CCNB1 | |
| SCHEMBL10070479 | 0.79 | PTPN11 (0.40) | — | |
| SCHEMBL10041198 | 0.78 | CDK5 (0.42) | CDK5CDK5R1GSK3BCDK1CCNB1 | |
| SCHEMBL10041199 | 0.76 | CDK5 (0.39) | CDK5CDK5R1GSK3BCDK1CCNB1 | |
| SCHEMBL10071039 | 0.74 | BCHE (0.31) | BCHEACHE | |
| SCHEMBL10041197 | 0.73 | ERN1 (0.39) | CDK5CDK5R1GSK3BCDK1CCNB1 | |
| SCHEMBL9943147 | 0.71 | CDK5 (0.33) | CDK5CDK5R1GSK3BMTNR1ACDK1 | |
| SCHEMBL10041200 | 0.69 | AKR1B1 (0.35) | CDK5CDK5R1GSK3BCDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120161089-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120161089-A1 | CHROMENE COMPOUND | CYP8B1, HSD3B2, CYP17A1 | CDK5 2524/4885CDK5R1 1160/4885GSK3B 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.